|Company Name||Revance Therapeutics, Inc.|
|Class Period||November 25, 2019 to October 11, 2021|
|Motion Deadline||February 8, 2022|
The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Revance Therapeutics, Inc. (NASDAQ: RVNC). The case is currently in the lead plaintiff stage. Investors who purchased RVNC securities between November 25, 2019 and October 11, 2021 may contact the Thornton Law Firm’s investor protection team by submitting their information above. Investors may also email firstname.lastname@example.org or call 617-531-3917.
The case alleges that Revance and its senior executives made misleading statements to investors and failed to disclose that: (i) quality control deficiencies existed at Revance Therapeutics’ manufacturing facility for DAXI; (ii) the foregoing deficiencies decreased the likelihood that the FDA would approve the DAXI BLA in its current form; and (iii) accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe Revance Therapeutics had represented to investors.
Interested Revance investors have until February 8, 2022 to retain counsel and apply to be a lead plaintiff if they are interested to do so. A lead plaintiff acts on behalf of all other investor class members in managing the class action. Investors do not need to be a lead plaintiff in order to be a class member. If investors choose to take no action, they can remain an absent class member. The class has not yet been certified. Until certification occurs, investors are not represented by an attorney. Thornton Law Firm is not currently representing a plaintiff who filed a complaint but is investigating the case on behalf of investors interested in being a lead plaintiff.
Thornton Law Firm’s securities attorneys are highly experienced in representing investors in recovering damages caused by violations of the securities laws. Its attorneys have established track records litigating securities cases in courts throughout the country and recovering losses on behalf of investors. This may be considered Attorney Advertising in some jurisdictions. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
A class action lawsuit has been filed on behalf of investors in Revance Therapeutics, Inc. (RVNC) securities.
Please use the form below to provide transaction information.